Final results and biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

This article has no abstract
Epistemonikos ID: b1cba4ec5039e534f5bbf446d4b53ab3812bf605
First added on: Feb 15, 2025